Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 34, 2014, Pages 3840-3847

  O'Shaughnessy, Joyce ^a,b   Hellerstedt, Beth ^a   Schwartzberg, Lee ^c,d   Yardley, Denise A ^e,f   Danso, Michael A ^g,h   Robert, Nicholas ⁱ   Richards, Paul ^j   Miller, Kathy D ^k   Rugo, Hope S ^l   Carlson, Robert W ^m   Finn, Richard S ^n,o   Neubauer, Marcus ^p   Saleh, Mansoor ^q   Specht, Jennifer M ^r   Charpentier, Eric ^s   Garcia Ribas, Ignacio ^s   Winer, Eric P ^t  

^a TEXAS ONCOLOGY   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c Accelerated Community Oncology Research Network   (United States)

^d WEST CLINIC   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f Tennessee Oncology   (United States)

^g Tennessee Oncology ^*  (United States)

^h Virginia Oncology Associates   (United States)

ⁱ Virginia Cancer Specialists   (United States)

^j Blue Ridge Cancer Care   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o Translational Oncology Research International   (United States)

^p Kansas City Cancer City   (United States)

^q Georgia Cancer Specialists   (United States)

^r UNIVERSITY OF WASHINGTON   (United States)

^s SANOFI   (United States)

^t DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; GEMCITABINE; INIPARIB; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DEOXYCYTIDINE;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONOTHERAPY; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UPPER GASTROINTESTINAL BLEEDING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES;

EID: 84912105634     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2984     Document Type: Article

References (24)

1. Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast 19:312-321, 2010
2. Cleere DW: Triple-negative breast cancer: A clinical update. Community Oncol 7:203-211, 2010
3. Coughlin SS, Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol 33:315-318, 2009
4. Carey LA: Directed therapy of subtypes of triple-negative breast cancer. Oncologist 15:49-56, 2010 (suppl 5)
5. Perou CM: Molecular stratification of triplenegative breast cancers. Oncologist 15:39-48, 2010 (suppl 5)
6. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
7. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
8. Dent R, Hanna W, Trudeau M, et al: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423-428, 2009
9. Foulkes WD, Smith I, Reis-Filho J: Triple-negative breast cancer. N Engl J Med 363:1938-1948, 2010
10. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007
11. Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer 9:29-33, 2009
12. Rottenberg S, Nygren AO, Pajic M, et al: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007 104:12117-12122, 2007
13. Isakoff SJ, Goss PE, Mayer EL, et al: Impact of BRCA1/2 mutation status in TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Res 72:P009-03, 2012 (suppl 24)
14. Chia JW, Ang P, See H, et al: Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy. J Clin Oncol 25:18s, 2007 (abstr 1086)
15. Koshy N, Quispe D, Shi R, et al: Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19:246-248, 2010
16. Baselga J, Gomez P, Greil R, et al: Randomized phase II study of the anti-epidermal growth factor receptor monocloncal antibody cetuximab with cisplatin versus cisplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 31:2586-2592, 2013
17. Hastak K, Alli E, Ford JM: Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 70:7970-7980, 2010
18. Chew HK, Doroshow JH, Frankel P, et al: Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27:2163-2169, 2009
19. Loesch D, Asmar L, McIntyre K, et al: Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 8:178-186, 2008
20. Yardley DA, Burris HA III, Simons L, et al: A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 8:425-431, 2008
21. Liu X, Shi Y, Magg DX, et al: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 18:510-523, 2012
22. Licht S, Cao H, Li Z, et al: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. Mol Cancer Ther 10:11, 2011 (suppl; abstr A226)
23. Ossovskaya V, Li L, Broude EV, et al: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer. American Association for Cancer Research Annual Meeting, April 18-22, 2009, Denver, CO (abstr 5552).
24. O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214, 2011